SGLT2i, Pioglitazone, and Ketone Production in T2D
Public ClinicalTrials.gov record NCT07053319. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Protocol lV: SGLT2 Inhibitors, Pioglitazone and Ketone Production in Type 2 Diabetes Mellitus
Study identification
- NCT ID
- NCT07053319
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Enrollment
- 64 participants
Conditions and interventions
Conditions
Interventions
- Empagliflozin 25 MG plus Pioglitazone placebo Drug
- Empagliflozin 25 mg/d plus Pioglitazone (15/30 mg/d) Drug
- Pioglitazone 15 mg increased to 30 mg after 2 weeks plus Empagliflozin Placebo Drug
- Pioglitazone placebo + Empagliflozin placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 30 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 19, 2026
- Primary completion
- May 31, 2027
- Completion
- Jun 29, 2027
- Last update posted
- Mar 12, 2026
2026 – 2027
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Texas Diabetes Institute/UH | San Antonio | Texas | 78229-3900 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07053319, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 12, 2026 · Synced Apr 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07053319 live on ClinicalTrials.gov.